Dr. Xu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-7000Fax+1 617-632-2165
Summary
- Dr. Wenxin Xu is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Harvard Medical School and completed residency and fellowship training at Beth Israel Deaconess Medical Center. He specializes in genitourinary oncology.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
Harvard Medical SchoolClass of 2014
Certifications & Licensure
NH State Medical License 2022 - 2026
MA State Medical License 2018 - 2025
ME State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Investigator Award Conquer Cancer Foundation, 2020
Publications & Presentations
PubMed
- Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research.Kenneth L Kehl, Justin Jee, Karl Pichotta, Morgan A Paul, Pavel Trukhanov
Nature Communications. 2024-11-12 - 2 citationsInsulin resistance during androgen deprivation therapy in men with prostate cancer.Shehzad Basaria, Mary-Ellen Taplin, Marie McDonnell, Donald C Simonson, Alexander P Lin
Cancer. 2024-11-01 - 1 citationsPlasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes.Wenxin Xu, Valerie Gaborieau, Samuel M Niman, Anush Mukeria, Xiaowen Liu
Journal of Clinical Oncology. 2024-08-01
Press Mentions
OncoHost Announces New Study on Biomarkers for Renal Cell CarcinomaJune 3rd, 2024- Dana-Farber Cancer Institute and OncoHost Partner for Renal Cell Carcinoma ResearchJune 13th, 2024
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
